An interventional study of vimida in Long COVID and Post COVID-19 Condition, sponsored by Gaia AG. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Gaia AG · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany — 14 open to participants now, 17 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Germany.
Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, this one is the 8th largest by enrollment of the 28 interventional ones that give a count, is one of 7 that started in 2025, is one of 20 with no phase, and was the 31st registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →14 of the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18+
Eggensberger OHG · Sites in Germany
Ages 18+
Max-Planck-Institute of Psychiatry · Sites in Germany
Ages 18–65
Schön Klinik Berchtesgadener Land · Sites in Germany
Ages 18+
Hellenic Institute for the Study of Sepsis · Sites in Germany, Greece, Italy and 1 more country
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 3
First in 2018; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 176 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 108 across the 28 interventional studies, 130 across the 13 observational. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 41 have an industry lead sponsor. The 10 most frequent:
Gaia AG is the lead sponsor of 21 studies on the registry; 3 are open to participants now.
Gaia AG has 1 study filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Post-Acute COVID-19 Syndrome with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07197138Max-Planck-Institute of PsychiatryIMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition | 2027-01 |
| NCT07110714Eggensberger OHGEffects of Kneipp Hydrotherapy in Post-COVID-19 Patients | 2027-01-31 |
| NCT07013903Schön Klinik Berchtesgadener LandEffects of Hydrotherapy During Post-COVID-19 Rehabilitation | 2027-01-31 |
| NCT06510985University Hospital TuebingenTranscutaneous Vagus Nerve Stimulation (tVNS) for Improved Recovery After Exertion. | 2027-05 |
| NCT05638724Technical University of MunichMunich Long COVID Registry for Children, Adolescents, and Adults | 2027-07-20 |
Add all 5 to your calendar (.ics) → With an account.
Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial (RCT) with 176 patients suffering from fatigue after COVID-19 infection aimed to investigate the effectiveness of the unguided digital therapeutic vimida for reducing post-COVID-19 fatigue. Inclusion criteria were: male, female or non-binary, age ≥18 years, diagnosis of post-COVID-19 fatigue, ≥3 months since the last infection with COVID-19, fatigue severity score (cut-off) of ≥16 on the Chalder Fatigue Scale (CFQ-11), stable treatment in the past 30 days, consent to participation, and sufficient German language skills. Exclusion criteria were plans to change treatment in the upcoming 3 months, a known psychiatric or somatic condition that can explain the fatigue, and current participation in a multidisciplinary rehabilitation program aimed to ameliorate the consequences of COVID-19.
Patients were randomized and allocated to either an intervention group, in which they received access to vimida in addition to treatment as usual (TAU; n=88), or to a control group, in which they received access to TAU only (n=88).
The primary endpoint was fatigue symptoms, with three months post-allocation (T1) as the primary time point for assessing effectiveness. Six months post-allocation (T2) was used as the follow-up assessment of the endpoints. Secondary endpoints were depressive symptoms, health-related quality of life, work/social functioning, somatic symptoms, and anxiety symptoms.
The criteria were revised on the registry on Nov 16, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants allocated to the intervention group received access to vimida in addition to treatment as usual (TAU). vimida is a digital health application designed for individuals with post-Covid conditions who suffer from fatigue, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by vimida are psychoeducation, activity and recovery, attention, stress management, sleep management, cognitive restructuring, and social resources. The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivational text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days.
Behavioral: vimida
Participants allocated to the control group received access to treatment as usual (TAU).
Participants will receive access to the digital health intervention vimida in addition to TAU.
Fatigue symptom severity
Chalder Fatigue Scale (CFQ-11). Total score ranging from 0-33; higher scores mean higher fatigue symptoms (worse outcome).
Time frame: 3 months
Depressive symptoms
Patient Health Questionnaire - 9 item version (PHQ-9). Total score ranging from 0-27; higher scores mean higher depressive symptoms (worse outcome).
Time frame: 3 months
Health-related quality of life
Assessment of Quality of Life - 8 Dimensions (AQoL-8D). Total score ranging from 0-100; higher scores mean higher quality of life (better outcome).
Time frame: 3 months
Functioning
Work and Social Adjustment Scale (WSAS). Total score ranging from 0-40; higher scores mean higher impairment (worse outcome).
Time frame: 3 months
Somatic symptoms
Patient Health Questionnaire - 15 item version (PHQ-15). Total score ranging from 0-30; higher scores mean higher somatic symptoms (worse outcome).
Time frame: 3 months
Anxiety
Generalized Anxiety Disorder Assessment (GAD-7). Total score ranging from 0-21; higher scores mean higher anxiety symptoms (worse outcome).
Time frame: 3 months
Fatigue symptom severity
Chalder Fatigue Scale (CFQ-11). Total score ranging from 0-33; higher scores mean higher fatigue symptoms (worse outcome).
Time frame: 6 months
Depressive symptoms
Patient Health Questionnaire - 9 item version (PHQ-9). Total score ranging from 0-27; higher scores mean higher depressive symptoms (worse outcome).
Time frame: 6 months
Health-related quality of life
Assessment of Quality of Life - 8 Dimensions (AQoL-8D). Total score ranging from 0-100; higher scores mean higher quality of life (better outcome).
Time frame: 6 months
Functioning
Work and Social Adjustment Scale (WSAS). Total score ranging from 0-40; higher scores mean higher impairment (worse outcome).
Time frame: 6 months
Somatic symptoms
Patient Health Questionnaire - 15 item version (PHQ-15). Total score ranging from 0-30; higher scores mean higher somatic symptoms (worse outcome).
Time frame: 6 months
Anxiety
Generalized Anxiety Disorder Assessment (GAD-7). Total score ranging from 0-21; higher scores mean higher anxiety symptoms (worse outcome).
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Sep 2025, 6 months.
Of 243 interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
Gaia AG